Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant monoclonal antibody to Abeta. Crenezumab is a humanized monoclonal antibody against human 1-40 and 1-42 Beta amyloid, which is being investigated as a treatment of Alzheimer's disease.
Target
Abeta
Type
IgG4 - kappa
Immunogen
Pegylated beta-Amyloid Peptide
Species Reactivity
Human
Expression Host
CHO
Applications
Suitable for use in WB, IF, IP, Neut, FuncS, ELISA, FC and most other immunological methods.
CAS
1174395-19-7
Specific Activity
Tested positive against native human antigen.
Protein Construction
Immunoglobulin G4, anti-(human 1-40- beta-amyloid/human 1-42- beta-amyloid) (human-mouse monoclonal MABT5102A heavy chain), disulfide with human-mouse monoclonal MABT5102A light chain, dimer
Predicted N terminal
H chain: EVQLVES; L chain: DIVMTQS
Molecular Weight
143330
Purity
>95%, by SDS-PAGE with silver staining, under reducing conditions.
Size
1mg
Storage
At -20°C for one year.
BACKGROUND
Antigen Description
Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Defects in APP are the cause of Alzheimer disease type 1 (AD1) [MIM:104300]. AD1 is a familial early-onset form of Alzheimer disease.
Function
DNA binding; PTB domain binding; acetylcholine receptor binding; heparin binding; identical protein binding; peptidase activator activity; peptidase inhibitor activity; protein binding; receptor binding; serine-type endopeptidase inhibitor activity; trans